Tags

Type your tag names separated by a space and hit enter

Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms.

Abstract

Anandamide is a ligand of the endocannabinoid system. Animals show a depletion following repeated Δ(9)-tetrahydrocannabinol (THC) administration but the effect of cannabis use on central nervous system levels of endocannabinoids has not been previously examined in humans. Cerebrospinal fluid (CSF) levels of the endocannabinoids anandamide, 2-arachidonoylglycerol (2-AG) and related lipids were tested in 33 volunteers (20 cannabis users). Lower levels of CSF anandamide and higher levels of 2-AG in serum were observed in frequent compared with infrequent cannabis users. Levels of CSF anandamide were negatively correlated with persisting psychotic symptoms when drug-free. Higher levels of anandamide are associated with a lower risk of psychotic symptoms following cannabis use.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Clinical Psychopharmacology Unit, UCL, London, UK. c.morgan@ucl.ac.uk

    , , , , , , ,

    Source

    MeSH

    Analysis of Variance
    Arachidonic Acids
    Endocannabinoids
    Female
    Glycerides
    Humans
    Male
    Marijuana Abuse
    Polyunsaturated Alkamides
    Psychotic Disorders
    Signal Transduction
    Young Adult

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    23580381

    Citation

    Morgan, Celia J A., et al. "Cerebrospinal Fluid Anandamide Levels, Cannabis Use and Psychotic-like Symptoms." The British Journal of Psychiatry : the Journal of Mental Science, vol. 202, no. 5, 2013, pp. 381-2.
    Morgan CJ, Page E, Schaefer C, et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry. 2013;202(5):381-2.
    Morgan, C. J., Page, E., Schaefer, C., Chatten, K., Manocha, A., Gulati, S., ... Leweke, F. M. (2013). Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. The British Journal of Psychiatry : the Journal of Mental Science, 202(5), pp. 381-2. doi:10.1192/bjp.bp.112.121178.
    Morgan CJ, et al. Cerebrospinal Fluid Anandamide Levels, Cannabis Use and Psychotic-like Symptoms. Br J Psychiatry. 2013;202(5):381-2. PubMed PMID: 23580381.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. AU - Morgan,Celia J A, AU - Page,Emma, AU - Schaefer,Carola, AU - Chatten,Katharine, AU - Manocha,Amod, AU - Gulati,Sumit, AU - Curran,H Valerie, AU - Brandner,Brigitta, AU - Leweke,F Markus, Y1 - 2013/04/11/ PY - 2013/4/13/entrez PY - 2013/4/13/pubmed PY - 2013/10/30/medline SP - 381 EP - 2 JF - The British journal of psychiatry : the journal of mental science JO - Br J Psychiatry VL - 202 IS - 5 N2 - Anandamide is a ligand of the endocannabinoid system. Animals show a depletion following repeated Δ(9)-tetrahydrocannabinol (THC) administration but the effect of cannabis use on central nervous system levels of endocannabinoids has not been previously examined in humans. Cerebrospinal fluid (CSF) levels of the endocannabinoids anandamide, 2-arachidonoylglycerol (2-AG) and related lipids were tested in 33 volunteers (20 cannabis users). Lower levels of CSF anandamide and higher levels of 2-AG in serum were observed in frequent compared with infrequent cannabis users. Levels of CSF anandamide were negatively correlated with persisting psychotic symptoms when drug-free. Higher levels of anandamide are associated with a lower risk of psychotic symptoms following cannabis use. SN - 1472-1465 UR - https://www.unboundmedicine.com/medline/citation/23580381/Cerebrospinal_fluid_anandamide_levels_cannabis_use_and_psychotic_like_symptoms_ L2 - https://www.cambridge.org/core/product/identifier/S0007125000274485/type/journal_article DB - PRIME DP - Unbound Medicine ER -